Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy

Carol S Yu1, Suk I Chiu, Chi S Ng

  • 1Department of Ophthalmology, Caritas Medical Center, 111 Wing Hong Street, Cheung Sha Wan, Hong Kong SAR, China. carolyushan@hotmail.com

Insights

Topical Mitomycin C (MMC) offers a successful treatment for localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. This approach achieved complete remission with minimal, manageable side effects in a case study.

Area of Science:

  • Ophthalmology
  • Oncology
  • Hematology

Background:

  • Conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is a rare, indolent non-Hodgkin's B-cell lymphoma.
  • Localized conjunctival MALT lymphoma presents a diagnostic and therapeutic challenge.

Observation:

  • A case report details a 35-year-old female with a two-year history of painless conjunctival masses.
  • Biopsy confirmed MALT lymphoma in both eyes.

Findings:

  • Four courses of topical 0.04% Mitomycin C (MMC) eyedrops were administered.
  • Complete regression of conjunctival lesions was achieved after treatment.
  • Repeat biopsy confirmed complete remission with transient, manageable side effects like conjunctival injection and punctate keratopathy.

Implications:

  • Topical MMC represents a novel and effective treatment for localized conjunctival MALT lymphoma.
  • This minimally invasive approach offers a promising alternative to systemic therapies.
  • Further research into topical MMC for ocular adnexal lymphomas is warranted.
Abstract